Inoviq (ASX:IIQ) says it has executed an agreement with MP Biomedicals for the contract manufacture of its proprietary SubB2M protein.
The protein is a key reagent used in Inoviq’s SubB2M-based tests for the monitoring and detection of cancer.
The company said the SubB2M specifically detects the pan-cancer biomarker Neu5Gc that is found in multiple human cancers, including breast, ovarian, prostate and others.
Manufacturing will take place in MP Biomedicals’ Singapore facility.
Inoviq holds the exclusive worldwide licence from the University of Adelaide to the SubB2M technology for use in diagnostic applications.
The company recently signed a master services agreement with US-based contract diagnostics organisation ResearchDx to further the development and validation of its SubB2M-based tests in the US.
Inoviq CEO Dr Leearne Hinch said, “Securing commercial supply of the SubB2M protein is a key milestone for INOVIQ. MP Biomedicals is a highly respected global supplier of life science and diagnostic products and we are therefore delighted to partner with them to ensure the commercial supply of SubB2M protein, which are critical components of our SubB2M-based tests for breast and ovarian cancer.”
MP Biomedicals’ director of sales and marketing Beng Kuan Choo added, “We are very excited to be partnering with INOVIQ to supply high-quality SubB2M protein for the Company’s innovative SubB2Mbased diagnostic tests. We are fully committed to deliver consistent supply of high-quality SubB2M as we believe that the SubB2M-based tests could play an important role in improving patient outcomes for monitoring breast, ovarian and other cancers.”
